A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer

Trial Profile

A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs SRA 737 (Primary) ; Cisplatin; Gemcitabine
  • Indications Anal cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Pancreatic cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Sierra Oncology
  • Most Recent Events

    • 03 Apr 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Oct 2019.
    • 27 Feb 2018 According to a Sierra Oncology media release, the Standard-Dose Triplet Combo Dose Escalation Phase 1 portion of this trial is completed and the Low-Dose Gemcitabine Combo Dose Escalation Phase 1 portion is anticipated to commence in the second quarter of 2018. Second portion is expanded to target enrollment of 80 genetically-selected patients across four indications.
    • 27 Feb 2018 According to a Sierra Oncology media release, preliminary data expected in the fourth quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top